Cutaneous manifestations of XXXX in patients receiving antithymocyte globulin.

@entity1 @entity3329 @entity203 @entity344 @entity925 @entity8667 @entity4841 @entity2131 @entity221 @entity110
We have prospectively evaluated the cutaneous manifestations of @entity8667 in thirty-five @entity1 treated with horse antithymocyte globulin for @entity2131 . Twenty-one @entity1 (21/35) were treated with antithymocyte globulin (15 mg/kg/day) for 10 days, and fourteen of thirty-five @entity1 were treated with antithymocyte globulin (15 mg/kg/day) for 14 days and then every other day for an additional 14 days. Clinical evidence of @entity8667 developed in thirty @entity1 and included @entity221 (100%), @entity203 (93%), @entity4841 and @entity925 (67%), @entity344 (67%), and @entity3329 (13%). Cutaneous findings consisted of morbilliform eruptions (n = 19), @entity110 (n = 1), or a combination of these two reaction patterns (n = 8). Cutaneous manifestations of @entity8667 began on day 7 +/- 1 and lasted for 12 +/- 2 days for the group as a whole. Biopsies of lesional skin revealed mild perivascular lymphohistiocytic infiltrates by light microscopy in these leukopenic @entity1 . Direct immunofluorescence microscopy of lesional skin from patients with @entity8667 demonstrated immunoreactants in seven of nine subjects (78%). Immunoreactants were confined to the walls of dermal blood vessels and consisted of IgM (7/9), C3 (6/9), IgE (5/9), and IgA (4/9). IgG (horse or @entity1 ) was not identified in any of these specimens. Twenty-one @entity1 (21/28) also developed an @entity203 on the sides of the fingers, toes, palms, and soles 12 to 48 hours prior to their morbilliform eruption. This study describes the cutaneous manifestations of human @entity8667 occurring during therapy with horse antithymocyte globulin, documents a cutaneous sign of @entity8667 , and suggests that the @entity203 associated with human @entity8667 are immunologically mediated.
